S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:MYGNMyriad Genetics Stock Price, Forecast & News

$13.11
+0.68 (+5.47 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.32
Now: $13.11
$13.11
50-Day Range
$10.69
MA: $11.76
$12.48
52-Week Range
$9.24
Now: $13.11
$47.10
Volume38,987 shs
Average Volume1.10 million shs
Market Capitalization$977.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
Myriad Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$851.10 million
Cash Flow$2.50 per share
Book Value$14.84 per share

Profitability

Net Income$4.60 million

Miscellaneous

Employees2,600
Market Cap$977.42 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableOptionable
$13.11
+0.68 (+5.47 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by Coronavirus?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MYGN shares have decreased by 6.6% and is now trading at $13.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Myriad Genetics
.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Myriad Genetics
.

How can I listen to Myriad Genetics' earnings call?

Myriad Genetics will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.10. The company had revenue of $164 million for the quarter, compared to the consensus estimate of $167.38 million. Myriad Genetics had a positive return on equity of 1.95% and a negative net margin of 19.49%. Myriad Genetics's revenue was down 24.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.46 earnings per share.
View Myriad Genetics' earnings history
.

What price target have analysts set for MYGN?

8 brokerages have issued 1 year price objectives for Myriad Genetics' stock. Their forecasts range from $10.00 to $36.00. On average, they anticipate Myriad Genetics' share price to reach $21.25 in the next year. This suggests a possible upside of 62.1% from the stock's current price.
View analysts' price targets for Myriad Genetics
.

Has Myriad Genetics been receiving favorable news coverage?

News articles about MYGN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myriad Genetics earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Myriad Genetics
.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.27%), New York State Common Retirement Fund (1.15%), Principal Financial Group Inc. (0.85%), CWM LLC (0.39%), Russell Investments Group Ltd. (0.29%) and Swiss National Bank (0.22%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Gary A King, John T Henderson, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, New York State Common Retirement Fund, UBS Group AG, First Quadrant L P CA, Texas Permanent School Fund, SG Americas Securities LLC, New York State Teachers Retirement System, and PNC Financial Services Group Inc..
View insider buying and selling activity for Myriad Genetics
.

Which major investors are buying Myriad Genetics stock?

MYGN stock was purchased by a variety of institutional investors in the last quarter, including Duality Advisers LP, Bank of New York Mellon Corp, Principal Financial Group Inc., Rafferty Asset Management LLC, Swiss National Bank, Envestnet Asset Management Inc., Strs Ohio, and Mackay Shields LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $13.11.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $977.42 million and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.